Skip to Main Content

Paper Details

Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
Clin Cancer Res
30
2020
AR, AR-, ARPC, ARPC PDX models, ARPC cell lines, ARPCs, AZD-1775, BCL2, MCC, Merkel cell carcinoma, RNA, SCNPC, SCNPC PDX, SCNPC PDX tumors, SCNPC cell lines, SCNPCs, Small, Small-cell Neuroendocrine Prostate Cancer, Small-cell neuroendocrine prostate cancer, Wee1, active prostate cancers, androgen, androgen receptor, navitoclax, neuroendocrine carcinomas, patient, prostate, prostate cancer, prostate cancer cell lines, small-cell lung cancer, tumor, tumors
Author NameAffiliation
Alexandra CorellaFred Hutchinson Cancer Research Center
Alexandra CorellaDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Ilsa ColemanFred Hutchinson Cancer Research Center
Ilsa ColemanDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Lawrence D TrueUniversity of Washington
Colm MorrisseyUniversity of Washington
Eva CoreyUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
  • 1 - 13

Datasets

Release 1.2